Showing 2911-2920 of 9152 results for "".
Analyzing Recent Deuruxolitinib Data
https://practicaldermatology.com/series/skin-minute/analyzing-recent-deuruxolitinib-data/57165/Arash Mostaghimi, MD, MPH, FAAD, Vice Chair of Clinical Trials and Innovation for the Brigham & Women's Hospital Department of Dermatology, discusses reently released data on deuruxolitinib for the treatment of alopecia areata.Pushing the Envelope in PN Research
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37181/Raja Sivamani, MD, MS, AP, an integrative dermatologist and Adjunct Associate Professor of Clinical Dermatology at the University of California, Davis, discusses how research to help understand different aspects of prurigo nodularis can help develop therapeutics that can be life-changing for patientFinding the Right Medication for the Right Patient with Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37180/Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, explains how to select the optimal therapeutic option for each different atopic dermatitis patient.The Role of Systemic Steroids in Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37139/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, discusses the role of systemic steroids in treating atopic dermatitis.The War Zone: Private Practice
https://practicaldermatology.com/series/the-practical-dermatology-podcast/the-war-zone-private-practice/54847/The War Zone: Private PracticePractical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Editorial Board member Collin Blattner, DO, FAAD, discuss strategies for building a successful private practice in the era of private equity, as well as the challenges associated with it.Strategies for Treating Patients on GLP-1 Receptor Agonists and More
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/strategies-for-treating-patients-on-glp-1-receptor-agonists-and-more/54646/Suneel Chilukuri, MD, discusses key takeaways from the “What’s My Treatment? How to Combine Dermal Filler, Neuromodulators, Laser/Light/RF Devices/Microneedling and Cosmeceuticals Symposium” workshop at Maui Derm Hawaii 2026.Evaluating Roflumilast for Seborrheic Dermatitis
https://practicaldermatology.com/series/skin-minute/evaluating-roflumilast-for-seborrheic-dermatitis/54610/Practical Dermatology Editorial Board member Raj Chovatiya, MD, PhD, MSCI, discusses results from the Phase 3 STRATUM trial studying the efficacy of roflumilast for the treatment of seborrheic dermatitis in patients with diverse skin types.Innovation in Androgenetic Alopecia
https://practicaldermatology.com/series/c-suite-chats/innovation-in-androgenetic-alopecia/54265/Diana Harbort, President of Cosmo Pharmaceuticals' Dermatology Division, discusses the need for new innovations in androgenetic alopecia and the promise of clascoterone for treating the condition.Unmet Needs in Atopic Dermatitis Management
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/unmet-needs-in-atopic-dermatitis-management/37145/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, says the most pressing unmet needs in atopic dermatitis management today involve the targets of therapyNonsurgical Skin Tightening and Facelifts
https://practicaldermatology.com/series/c-suite-chats/nonsurgical-skin-tightening-and-facelifts/54266/Kim Laudati, founder and president of SomaCell, discusses recent demand for minimally invasive, natural-looking treatments and how her company's nonsurgical skin tightening and facelifts help address that trend.